Latest market price
237.32
-0.08-0.03%
TA
Loading chart...
Snapshot
| Index | S&P 500 | P/E | 125.57 | EPS (ttm) | 1.89 | Insider Own | 0.74% | Shs Outstand | 720.57M | Perf Week | 1.05% |
| Market Cap | 171.01B | Forward P/E | 73.15 | EPS next Y | 3.24 | Insider Trans | 0.19% | Shs Float | 719.74M | Perf Month | 1.59% |
| Enterprise Value | 188.76B | PEG | 6.47 | EPS next Q | - | Inst Own | 61.08% | Short Float | 2.47% | Perf Quarter | -4.44% |
| Income | 1.35B | P/S | 13.56 | EPS this Y | 56.23% | Inst Trans | 0.00% | Short Ratio | 6.25 | Perf Half Y | 13.69% |
| Sales | 12.61B | P/B | 3.60 | EPS next Y | 13.70% | ROA | 1.93% | Short Interest | 17.74M | Perf YTD | 27.86% |
| Book/sh | 65.84 | P/C | 87.03 | EPS next 5Y | 19.40% | ROE | 3.15% | 52W High | 255.21 -7.01% | Perf Year | 34.89% |
| Cash/sh | 2.73 | P/FCF | 64.24 | EPS past 3/5Y | 66.71% -9.82% | ROIC | 0.96% | 52W Low | 174.90 35.69% | Perf 3Y | 176.73% |
| Dividend Est. | 3.40 (1.43%) | EV/EBITDA | 62.57 | Sales past 3/5Y | 22.69% 18.39% | Gross Margin | 38.82% | Volatility | 2.10% 2.07% | Perf 5Y | 182.15% |
| Dividend TTM | 3.07 (1.29%) | EV/Sales | 14.97 | EPS Y/Y TTM | 20.38% | Oper. Margin | 5.40% | ATR (14) | 4.98 | Perf 10Y | 239.56% |
| Dividend Ex-Date | Aug 12, 2026 | Quick Ratio | 0.84 | Sales Y/Y TTM | 60.59% | Profit Margin | 10.67% | RSI (14) | 58.11 | Recom | 2.19 |
| Dividend Gr. 3/5Y | 4.94% 0.87% | Current Ratio | 0.84 | EPS Q/Q | 32.61% | SMA20 | 2.89% | Beta | 0.79 | Target Price | 257.23 |
| Payout | 152.41% | Debt/Eq | 0.49 | Sales Q/Q | 40.90% | SMA50 | 1.51% | Rel Volume | 0.76 | Prev Close | 237.40 |
| Employees | 712 | LT Debt/Eq | 0.49 | Earnings | Oct 26 | SMA200 | 9.19% | Avg Volume | 2.75M | Price | 237.32 |
| IPO Date | Mar 19, 1980 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -1.18% 4.15% | Net Debt/EBITDA | 5.89 | Volume | 2,099,533 | Change | -0.03% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-19-26 | Reiterated | Wells Fargo | Overweight | $266 → $268 |
| Oct-13-26 | Reiterated | Barclays | Equal Weight | $259 → $246 |
| Sep-24-26 | Upgrade | JP Morgan | Neutral → Overweight | |
| Sep-21-26 | Reiterated | Evercore ISI Group | Outperform | $260 → $256 |
| Sep-15-26 | Reiterated | Jefferies | Buy | $248 → $275 |
| Sep-02-26 | Reiterated | Scotiabank | Sector Outperform | $248 → $251 |
| Sep-01-26 | Reiterated | Wells Fargo | Overweight | $218 → $266 |
| Sep-01-26 | Reiterated | Morgan Stanley | Overweight | $215 → $251 |
| Aug-31-26 | Reiterated | Barclays | Equal Weight | $254 → $259 |
| Aug-04-26 | Reiterated | Keybanc | Overweight | $240 → $275 |
Latest News· Times ET
Oct-23-26
Oct-22-26
Oct-22-2609:17AM
Oct-21-26
Oct-21-2604:46PM
11:30AM
06:45AM
Oct-17-26
Oct-16-26
Oct-16-2607:00AM
Oct-15-26
Oct-15-2604:03PM
Oct-14-26
Oct-14-2602:04PM
08:45AM
Oct-13-26
Oct-13-2604:15PM
Oct-12-26
02:02AM
Real Estate Stocks To Consider – October 10thdefenseworld.net
Oct-07-26
08:15AM
Company
Welltower Inc. (NYSE:WELL), an S&P 500 company based in Toledo, Ohio, is a leader in reshaping healthcare infrastructure. This Real Estate Investment Trust (REIT) strategically collaborates with premier operators in seniors housing, post-acute care, and health systems. Their core mission is to finance the vital property assets required to expand innovative care delivery models, thereby enhancing overall public wellness and healthcare experiences. Welltower's portfolio encompasses a variety of properties, including seniors housing, post-acute communities, and outpatient medical facilities, all situated primarily within key, rapidly growing markets across the United States, Canada, and the United Kingdom.
Ownership
Total institutional ownership61.08%
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 12,613 | 10,667 | 7,854 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 7,716 | 6,488 | 4,830 | — | — | — | — | — | — | |
| Gross Profit | 4,895 | 4,179 | 3,023 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 1,754 | 1,748 | 235 | — | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | — | — | — | — | — | — | |
| Other Operating Expense | 2,461 | 2,076 | 1,643 | — | — | — | — | — | — | |
| Operating Income | 680 | 355 | 1,146 | — | — | — | — | — | — | |
| Interest Expense | 741 | 652 | 574 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 1,541 | 1,252 | 404 | — | — | — | — | — | — | |
| Net Income Before Taxes | 1,482 | 955 | 976 | — | — | — | — | — | — | |
| Income Taxes | 71 | -7 | 3 | — | — | — | — | — | — | |
| Consolidated Net Income | 1,346 | 937 | 952 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 1,410 | 962 | 973 | — | — | — | — | — | — | |
| Net Income | 1,346 | 937 | 952 | — | — | — | — | — | — | |
| EPS (Recurring) | 1.93 | 1.41 | 1.58 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.93 | 1.41 | 1.58 | — | — | — | — | — | — | |
| EPS (Diluted) | 1.89 | 1.39 | 1.57 | — | — | — | — | — | — | |
| EBITDA | 3,017 | 2,310 | 2,778 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 125.57 | 133.53 | 80.27 | — | — | — | — | — | — | |
| Price To Sales Ratio | 13.26 | 11.59 | 9.68 | — | — | — | — | — | — | |
| Gross Margin | 38.81 | 39.18 | 38.49 | — | — | — | — | — | — | |
| Operating Margin | 5.39 | 3.33 | 14.59 | — | — | — | — | — | — | |
| Net Margin | 10.67 | 8.78 | 12.12 | — | — | — | — | — | — | |
| Shares Outstanding | 705 | 666 | 603 | — | — | — | — | — | — | |
| Market Capitalization | 167,311 | 123,616 | 75,996 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Gundlach Andrew | Director | Aug 26 '26 | Buy | 242.06 | 5,000 | 1,210,300 | 30,000 | Aug 27 |
| Gundlach Andrew | Director | Aug 25 '26 | Buy | 239.47 | 5,000 | 1,197,350 | 25,000 | Aug 27 |
| Gundlach Andrew | Director | Jun 30 '25 | Buy | 151.46 | 20,000 | 3,029,200 | 20,000 | Jul 02 |
| Mitra Shankh | CEO | Jun 06 '25 | Sale | 152.48 | 86,219 | 13,146,636 | 17,258 | Jun 11 |
| Mcqueen Matthew Grant | Chief Legal Officer | Jun 06 '25 | Sale | 152.48 | 8,854 | 1,350,000 | 7,565 | Jun 10 |
| Burkart John F. | Vice Chairman and COO | Jun 06 '25 | Sale | 152.48 | 8,854 | 1,350,000 | 1,318 | Jun 10 |
| McHugh Timothy | Co-President and CFO | Jun 06 '25 | Sale | 152.48 | 13,116 | 2,000,000 | 12,884 | Jun 10 |
| Chaudhri Nikhil | Co-President and CIO | Jun 06 '25 | Sale | 152.48 | 10,527 | 1,605,229 | 0 | Jun 10 |
| DeSalvo Karen B | Director | Apr 30 '24 | Sale | 151.43 | 4,000 | 605,720 | 11,314 | May 01 |
| Fieweger Joshua | SVP, Chief Accounting Officer | Feb 18 '25 | Option Exercise | 74.86 | 18,496 | 1,384,518 | 25,025 | Feb 24 |
| BACON KENNETH J | Director | Dec 09 '24 | Sale | 130.19 | 2,200 | 286,418 | 12,379 | Dec 10 |
| BACON KENNETH J | Director | Jun 04 '24 | Sale | 103.91 | 1,800 | 187,038 | 14,579 | Jun 05 |
| Fieweger Joshua | SVP, Chief Accounting Officer | Feb 13 '24 | Option Exercise | 0.00 | 13,138 | 0 | 17,746 | Feb 15 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.